Welcome to LookChem.com Sign In|Join Free

CAS

  • or

865363-93-5

Post Buying Request

865363-93-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • E2FDA/ MK-8591/4'-ethynyl-2-fluoro-2'-deoxyadenosine/ reagent/nucleoside/ white powder with cas no. 865363-93-5/ worldwide Top Pharma factory vendor with most competitive price

    Cas No: 865363-93-5

  • USD $ 4500.0-6150.0 / Gram

  • 1 Gram

  • 10 Kilogram/Month

  • YUNBIO TECH CO.,LTD
  • Contact Supplier

865363-93-5 Usage

Uses

Different sources of media describe the Uses of 865363-93-5 differently. You can refer to the following data:
1. 4'-ethynyl-2-fluoro-2'-deoxyadenosine is a heterocyclic organic compound and can be used as pharmaceutical intermediates.
2. MK-?8591 is a carbocyclic nucleoside reverse transcriptase translocation inhibitor and is used as an antiviral with potential use towards the treatment of HIV.

Check Digit Verification of cas no

The CAS Registry Mumber 865363-93-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,3,6 and 3 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 865363-93:
(8*8)+(7*6)+(6*5)+(5*3)+(4*6)+(3*3)+(2*9)+(1*3)=205
205 % 10 = 5
So 865363-93-5 is a valid CAS Registry Number.

865363-93-5Downstream Products

865363-93-5Relevant articles and documents

Nine-Step Stereoselective Synthesis of Islatravir from Deoxyribose

Nawrat, Christopher C.,Whittaker, Aaron M.,Huffman, Mark A.,McLaughlin, Mark,Cohen, Ryan D.,Andreani, Teresa,Ding, Bangwei,Li, Hongming,Weisel, Mark,Tschaen, David M.

, p. 2167 - 2172 (2020)

A stereoselective nine-step synthesis of the potent HIV nucleoside reverse transcriptase translocation inhibitor (NRTTI) islatravir (EfdA, MK-8591) from 2-deoxyribose is described. Key findings include a diastereodivergent addition of an acetylide nucleophile to an enolizable ketone, a chemoselective ozonolysis of a terminal olefin and a biocatalytic glycosylation cascade that uses a unique strategy of byproduct precipitation to drive an otherwise-reversible transformation forward.

Enantioselective Synthesis of 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) via Enzymatic Desymmetrization

McLaughlin, Mark,Kong, Jongrock,Belyk, Kevin M.,Chen, Billy,Gibson, Andrew W.,Keen, Stephen P.,Lieberman, David R.,Milczek, Erika M.,Moore, Jeffrey C.,Murray, David,Peng, Feng,Qi, Ji,Reamer, Robert A.,Song, Zhiguo J.,Tan, Lushi,Wang, Lin,Williams, Michael J.

, p. 926 - 929 (2017)

An enantioselective synthesis of the potent anti-HIV nucleoside EFdA is presented. Key features of stereocontrol include construction of the fully substituted 4′-carbon via a biocatalytic desymmetrization of 2-hydroxy-2-((triisopropylsilyl)ethynyl)propane-1,3-diyl diacetate and a Noyori-type asymmetric transfer hydrogenation to control the stereochemistry of the 3′-hydroxyl bearing carbon. The discovery of a selective crystallization of an N-silyl nucleoside intermediate enabled isolation of the desired β-anomer from the glycosylation step.

Synthesis of nucleotide analogues, EFdA, EdA and EdAP, and the effect of EdAP on hepatitis B virus replication

Kamata, Mai,Takeuchi, Toshifumi,Hayashi, Ei,Nishioka, Kazane,Oshima, Mizuki,Iwamoto, Masashi,Nishiuchi, Kota,Kamo, Shogo,Tomoshige, Shusuke,Watashi, Koichi,Kamisuki, Shinji,Ohrui, Hiroshi,Sugawara, Fumio,Kuramochi, Kouji

, p. 217 - 227 (2020)

4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) and 4′-ethynyl-2′-deoxyadenosine (EdA) are nucleoside analogues which inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. EdAP, a cyclosaligenyl (cycloSal) phosphate derivative of EdA, inhibits the replication of the influenza A virus. The common structural feature of these compounds is the ethynyl group at the 4′-position. In this study, these nucleoside analogues were prepared by a common synthetic strategy starting from the known 1,2-di-O-acetyl-D-ribofuranose. Biological evaluation of EdAP revealed that this compound reduced hepatitis B virus (HBV) replication dose-dependently without cytotoxicity against host cells tested in this study.

ENGINEERED PURINE NUCLEOSIDE PHOSPHORYLASE VARIANT ENZYMES

-

Paragraph 0192-0194; 0200-0208, (2020/02/06)

The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 865363-93-5